Abstract：Objective To study the relationship between the suppression of the hypothalamic-pituitary-gonadal axis (HPGA) and the predicted adult height (PAH) in girls with central precocious puberty (CPP) during the treatment with gonadotropin-releasing hormone analogue (GnRHa), in order to provide guidance for individualized GnRHa dose adjustment in clinical practice. Methods The clinical data of 75 CPP girls were collected, and then height, bone age (BA), uterine and ovarian volumes, and peak luteinizing hormone (LH), peak follicle-stimulating hormone (FSH), and estradiol (E2) levels were recorded at different time points of GnRHa treatment. PAH at each time point was calculated. PAH improvement (ΔPAH=PAH-target height) and its relationship with the degree of HPGA suppression were analyzed. Threshold effect analysis was applied to determine the best HPGA suppression range forΔPAH. Results After GnRHa treatment, PAHs were improved markedly compared with the data in the early stage of treatment. ΔPAH showed a negative correlation with ΔBA. At 24 months of treatment, ΔPAH was also negatively correlated with LH. Uterine volume controlled between 2.3 and 3.0 mL, LH level controlled below 0.8 IU/L, and FSH controlled below 2.4 IU/L could slow down the growth of BA and improve PAH. Conclusions GnRHa treatment can improve the PAH of CPP girls. Selection of an appropriate therapeutic dose for GnRHa to control uterine volume, LH and FSH levels within certain ranges can slow down the growth of BA and improve PAH.
TAO Yue-Hong,ZENG Bi-He,Nazir Sharif. Effects of HPGA suppression on predicted adult height in girls with central precocious puberty[J]. CJCP, 2015, 17(10): 1093-1097.
Kim EY. Long-term effects of gonadotropin-releasing hormone analogs in girls with central precocious puberty[J]. Korean J Pediatr, 2015, 58(1):1-7.
[3]
Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children[J]. Pediatrics, 2009, 123(4):e752-e762.
Brito VN, Latronico AC, Cukier P, et al. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin releasing hormone analogs[J]. Clin Endocrinol Metab, 2008, 93(7):2662-2669.
[11]
Fuld K, Chi C, Neely EK. A randomized trial of 1-and 3-month depot leuprolide doses in the treatment of central precocious puberty[J]. J Pediatr, 2011, 159(6):982-987.
Kim YJ, Lee HS, Lee YJ, et al. Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty[J]. Ann Pediatr Endocrinol Metab, 2013, 18(4):173-178.
[14]
Demirbilek H, Alikasifoglu A, Gonc NE, et al. Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty;validity of single luteinizing hormone measurement after leuprolide acetate injection[J]. Clin Endocrinol (Oxf), 2012, 76(1):126-130.
Neely EK, Lee PA, Bloch CA, et al. Leuprolide acetate 1-month depot for central precocious puberty:hormonal suppression and recovery[J]. Int J Pediatr Endocrinol, 2010, 2010:398639.
